HealthTree Logo
search more_vert
person Sign In / Create Account
Is MRD Negativity the Goal of Myeloma Treatment?
Is MRD Negativity the Goal of Myeloma Treatment? image
Minimal Residual Disease (MRD)
event Jun 18, 2024 / 01:00PM - 02:00PM EDT

Video Recording Coming Soon

Event Description

Join us to discuss minimal residual disease results with myeloma specialist Dr. Malin Hultcrantz. Should the end goal of all treatment regimens be achieving MRD negativity? If it's not achieved with the initial treatment, should therapy be adjusted to achieve MRD negativity even if the patient is in a complete response? 

Come with your questions as we learn together!

Schedule & Agenda

The panelist Cynthia Cahoon
1:00 PM
Cynthia Cahoon

Cynthia introduces the agenda of the event and our featured speaker Dr. Malin Hultcrantz.

The panelist Malin Hultcrantz, MD, PhD
1:05 PM
Malin Hultcrantz, MD, PhD

Dr. Hultcrantz shares her thoughts on MRD negativity.

Questions and Answers
1:35 PM

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Malin Hultcrantz, MD, PhD
Malin Hultcrantz, MD, PhD

Malin Hultcrantz, MD, PhD, is a board-certified hematologist who specializes in the treatment of multiple myeloma and related plasma cell disorders including the precursor disorders monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma at the Memorial Sloan Kettering Cancer Center. She is focused on further optimizing treatment strategies for people with multiple myeloma, and offers a variety of modern treatments including clinic trials and novel immunotherapies. She is also working on measures to continue to improve patients’ quality of life while receiving treatment for multiple myeloma. Additionally, she has a particular interest in studying mechanisms and markers of progression from precursor disease to multiple myeloma. As part of this effort, she is working with her colleagues to develop targeted genomic tests for disease characterization and measurement of minimal residual disease. Better understanding of disease biology allows for better risk stratification and personalized treatment including early treatment for patients with high-risk precursor disease. In 2015, Dr. Hultcrantz received the Research Fellow Award, Multiple Myeloma Research Foundation and the International Postdoc Award, Swedish Research Council. Dr. Hultcrantz is fluent in Swedish and English.

Read Bio
The panelist Cynthia Cahoon
Cynthia Cahoon

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life long learning and enjoys sharing what she learns with the people around her.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us




Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube